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ABSTRACT
Background. The pharmacokinetics of oxycodone in patients
with end-stage renal disease (ESRD) requiring haemodialysis
are largely unknown. Therefore, we investigated the pharmaco-
kinetics of oxycodone/naloxone prolonged release and their
metabolites in patients with ESRD during and between haemo-
dialysis sessions.
Methods. Single doses of oxycodone/naloxone (5/2.5 or 10/
5mg) were administered in nine patients with ESRD using a
cross-over design on the day of dialysis and on a day between
dialysis sessions. Plasma, dialysate and urine concentrations of
oxycodone, naloxone and their metabolites were determined up
to 48h post-dosing using a liquid chromatography–tandem
mass spectrometry system.
Results.Haemodialysis performed 6–10 h after dosing removed
10% of the administered dose of oxycodone predominantly as
unconjugated oxycodone and noroxycodone or conjugated oxy-
morphone and noroxymorphone. The haemodialysis clearance
of oxycodone based on its recovery in dialysate was (mean 6
SD) 8.46 2.1 L/h. The geometric mean (coefficient of variation)
plasma elimination half-life of oxycodone during the 4-h hae-
modialysis period was 3.9 h (39%) which was significantly
shorter than the 5.7 h (22%) without haemodialysis. Plasma lev-
els of the active metabolite oxymorphone in its unconjugated
formwere very low.
Conclusions. Oxycodone is removed during haemodialysis. The
pharmacokinetics including the relatively short half-life of oxyco-
done in patients with ESRD with or without haemodialysis and
the absence of unconjugated active metabolites indicate that oxy-
codone can be used at usual doses in patients requiring dialysis.
Keywords: haemodialysis, naloxone, oxycodone, pharmacoki-
netics, renal failure
INTRODUCTION
The oxycodone/naloxone prolonged release (PR) combination
is licensed in Switzerland for the treatment of moderate to se-
vere pain that cannot be adequately managed with non-opioid
analgesics. The opioid antagonist component naloxone is for
the treatment and prevention of opioid-induced constipation
[1–3]. Opioids are frequently prescribed in patients with ad-
vanced illnesses who may also have end-stage renal disease
(ESRD) requiring haemodialysis [4]. The pharmacokinetics of
oxycodone/naloxone PR in such patients are largely unknown.
Oxycodone has a high oral bioavailability of 50–87% [5, 6].
It is metabolized mainly via CYP3A4-mediated N-demethyla-
tion to noroxycodone and via CYP2D6-meidated O-demethyl-
ation to oxymorphone [7, 8]. Noroxycodone is considered to be
the main metabolite of oxycodone [5, 7–9]. It is pharmacologi-
cally active at the m-opioid receptor, but 5-fold less potent than
oxycodone [10]. Oxymorphone, on the other hand, is 8-fold
more potent than oxycodone [10–12]. The formation of oxy-
morphone is dependent on the function of polymorphic
CYP2D6 [8, 13, 14]. Both metabolites are further metabolized
to noroxymorphone, which is only weakly active [10].
Oxycodone and all its metabolites are ultimately glucuronidated
[15]. Whether the glucuronide metabolites are active is un-
known. Many studies have investigated pharmacokinetics of
oxycodone and its metabolites in subjects with normal renal
function [5, 6, 13, 16–19], including the influence of drug–drug
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interactions and CYP2D6 polymorphisms [8, 13, 17, 20–26].
However, there is only limited information in patients with
ESRD [19, 27, 28]. In a previous study, pharmacokinetic pro-
files were assessed up to 24 h after administration of intrave-
nous oxycodone (0.07mg/kg) in 10 patients with ESRD during
general anaesthesia for renal transplantation surgery and com-
pared with 10 patients with normal renal function undergoing
general surgery [19]. The plasma elimination half-life of oxyco-
done was prolonged and highly variable (mean 6 SD: 76 7 h)
compared with that in patients with normal renal function
(3.46 1 h) [19]. Possible accumulation of oxycodone was
reported in a single haemodialysis patient [28], while safe use
and removal by haemodialysis was reported in another case
[27]. Systematic data on the pharmacokinetics of oxycodone
and its metabolites in patients with ESRD not currently under-
going surgery or during dialysis itself are, however, completely
lacking.
Our primary goal was to describe the pharmacokinetics of
oxycodone, naloxone, their metabolites oxymorphone, noroxy-
codone, noroxymorphone and respective glucuronides after a
single dose of oxycodone/naloxone PR in patients with ESRD
during and between intermittent haemodialysis sessions.
MATERIALS AND METHODS
Study design
Single doses of oral oxycodone/naloxone PR (5/2.5 or 10/
5mg) were administered in patients with ESRD undergoing in-
termittent haemodialysis using a cross-over design with two
randomly assigned conditions (with and without haemodialy-
sis). The washout periods between the test days were at least 7
days. The study was approved by the local Ethics Committee
and the Swiss Agency for Therapeutic Products (Swissmedic),
and conducted in accordance with the Declaration of Helsinki.
All subjects provided written consent before participating in the
study, and they were paid for their participation. The study was
registered at EudraCT (EudraCT no: 2013-005022-30) and per-
formed betweenMay 2014 andMarch 2017.
Patient selection
Male and female outpatients with ESRD requiring haemo-
dialysis aged between 18 and 80 years were recruited from the
dialysis centres of the University Hospital Basel and Medical
University Clinic, Kantonsspital Baselland, Switzerland.
Exclusion criteria included: body mass index <18 or >40 kg/
m2; body weight <50 kg; pregnant or lactating women; severe
cardiovascular disease (myocardial infarction within the last
6months, New York Heart Association class III and IV); hae-
matological disease; acute or severe bronchial asthma or hyper-
capnia; respiratory depression; paralytic ileus; neoplasia;
moderate to severe hepatic impairment; severe deviations from
normal values in the routine laboratory tests not explained by
the ESRD; major abnormalities in physical examination (in par-
ticular: systolic blood pressure >180 or <90mm Hg, diastolic
blood pressure <50 or >105mm Hg, heart rate <50 or >120
bpm, respiratory rate <8 or >24 breaths/min; abnormalities
likely to affect the volume of distribution, e.g. severe oedema),
vital signs or electrocardiogram (signs of acute ischaemia, ab-
normal heart rhythm and any change in ECG from the last rou-
tinely recorded ECG); concomitant use of opioids or
contraindication against their use; concomitant use of mono-
amine oxidase inhibitors, CYP3A4 and/or CYP2D6 inhibitors
and/or CYP3A4 inducers within 2weeks before study start.
Participants were genotyped for CYP2D6 function as described
previously [29]. A total of 47 patients were screened and 10
patients (three women and seven men) with a mean age of
52 years were included. Screening failures included 12 patients
who were not interested in taking part in the study; 23 who met
exclusion criteria and one who was not available on the planned
study dates. There were two drop-outs during the study: one
participant (no. 3) was called up for renal transplantation 10h
into the first study session and one patient (no. 5) stopped study
participation after the first session because she developed uri-
nary retention. The final study sample therefore consisted of
eight patients who completed both test days in the cross-over
design and nine patients with intradialysis kinetic data. The pa-
tient and haemodialysis characteristics are shown in Table 1.
Study procedures
Patients were admitted to the study centre at 6.30 a.m. and
the study drug was administered at 7.00 a.m. On that day, hae-
modialysis started at 1 p.m., which was 6 h after administration
of oxycodone/naloxone. The duration of dialysis was according
to patients’ clinical needs and was on average 4
h (2456 22min). Dialysis was performed by trained staff on
the haemodialysis unit in a standardized fashion using a
Fresenius HF80 polysulfone hollow-fibre high-flux haemodia-
lyser (Fresenius Medical Care, Oberdorf, Switzerland). Patients
stayed in the study centre for 24 h. An additional blood sample
was collected during a visit 48 h after dosing.
Study drug
Oxycodone/naloxone PR (TarginVR , Mundipharma Medical
Company, Basel Branch) was administered at a dose of 5/
2.5mg to four patients and 10/5mg to five patients. The 10/
5mg dose contains 10mg of oxycodone hydrochloride (9mg of
oxycodone) and 5mg of naloxone hydrochloride (4.5mg of nal-
oxone). The study was initially designed using oxycodone/nal-
oxone 10/5mg to maximize the likelihood of being able to
determine low drug and metabolite concentrations, while mini-
mizing the occurrence of adverse effects. Interim laboratory
analyses revealed good sensitivity of the test method at low con-
centrations and this, coupled with the development of urinary
retention and vomiting in another subject, prompted a protocol
amendment to continue the study using oxycodone/naloxone
PR 5/2.5mg.
Measures
Blood, dialysate and urine sampling. Blood was collected
into lithium heparin tubes before and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7,
8, 9, 10, 12, 18, 24 and 48 h after oxycodone/naloxone adminis-
tration. During haemodialysis, both ‘arterial’ and ‘venous’ blood
(the line entering and exiting the dialysis system, respectively)
and dialysate samples were collected at 6, 7, 8, 9 and 10 h after
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oxycodone/naloxone administration. The plasma and dialysate
samples were stored at 80C until analysis. Total urine was
sampled in those subjects who produced urine for 24 h after
dosing.
Analysis of oxycodone, naloxone and metabolite
concentrations. Plasma, dialysate and urine concentrations
of oxycodone, naloxone, oxymorphone, noroxycodone and nor-
oxymorphone were measured before and after enzymatic deglu-
curonidation [7] using a high-pressure liquid chromatography–
tandem mass spectrometry system as described in the
Supplementary material online. Concentrations of the glucuro-
nidated (conjugated) analytes were determined indirectly by
measuring the analytes after deglucuronidation and subtracting
the amount of unconjugated analytes. Results are expressed in
units of deconjugated analytes.
Pharmacodynamics
Subjective effects. Visual analogue scales (VASs) were re-
peatedly used at the times of blood sampling to assess subjective
effects over time. The VASs included separate measures for
‘tiredness’, ‘nausea’, ‘itching’ and ‘irritability’, and were pre-
sented as 100-mm horizontal lines (0–100%) marked from ‘not
at all’ on the left to ‘extremely’ on the right.
Pupillary response. Pupillometry was performed before and
repeatedly after oxycodone/naloxone administration using a
hand-held PRL 200 infrared pupillometer (NeurOptics, Irvine,
CA, USA). Pupil function was measured under standardized
dark–light conditions and assessed by a Voltcraft MS-1300 lux-
meter (Voltcraft, Hirschau, Germany) following a dark adap-
tion time of 1min as previously described [30].
Pharmacokinetic analyses
Blood plasma pharmacokinetics. Non-compartmental
analyses were performed using Phoenix WinNonlin 6.4
(Certara, Princeton, NJ, USA). Peak plasma concentration
(Cmax) and time to Cmax (Tmax) were obtained directly from the
observed data. The terminal elimination rate constant (kz) was
estimated by log-linear regression after semi-logarithmic trans-
formation of the data using data points of the terminal linear
phase of the concentration–time curve (after the end of haemo-
dialysis on the dialysis day). The terminal half-life (t1/2) was cal-
culated using kz and the equation t1/2 ¼ ln2/kz. We also
determined the elimination rate constant for oxycodone during
the haemodialysis session using the data points obtained at 6, 7,
8, 9 and 10 h after drug administration to calculate the half-life
during haemodialysis (t1/2d). The area under the plasma con-
centration–time curve (AUC) from 0 to 48 h after dosing
(AUC48) was calculated using the linear up/log down method.
The AUC to infinity (AUC1) was determined by extrapolation
of the AUC48 by using kz. The AUC from 6 to 10 h (AUC6–10)
was also calculated to assess the influence of haemodialysis on
plasma oxycodone and analyte concentrations during
haemodialysis.
Haemodialysis pharmacokinetics. The amount of analyte
eliminated by haemodialysis and recovered in the dialysate was
calculated as follows: Ad ¼ Cd, 6–10Vd, with Cd, 6–10 being the
mean concentration of the analyte in the dialysate and Vd the
total dialysate volume (volume/4 h). The clearance by haemo-
dialysis was then calculated using the ‘recovery method’ as fol-
lows: CLh, r ¼ Ad/AUCart, 6–10 with AUCart, 6–10 being the AUC
in arterial blood plasma taken from the line entering the dialysis
system from start to end of the haemodialysis. The haemodialy-
sis clearance (CLh, e) was also calculated by the ‘extraction
method’ as follows: CLh ¼ Q E where Q is the haemodialysis
blood flow and E is the drug extraction ratio by haemodialysis.
E was calculated as follows: E ¼ (CaCv)/Ca, where Ca is the
concentration of the analyte in arterial blood plasma entering
the dialysis system and Cv is the concentration of the analyte in
the blood plasma exiting the dialysis system and entering the
venous system of the patient.
Statistical analyses
The analysis of the pharmacokinetic parameters was de-
scriptive. Geometric means, percentage coefficients of variation
(CV%) and summary statistics for the graphs were calculated
within WinNonlin. The pharmacokinetic parameters with and
without haemodialysis were then compared within subjects us-
ing paired T-tests (Statistica 12 software; StatSoft, Tulsa, OK,
USA). Parameters are shown for each dose separately (n¼ 4
and 5 for 5/2.5 and 10/5mg of oxycodone/naloxone, respec-
tively). For the main analyte oxycodone, data standardized to
the 10/5mg dose are also shown for the whole group. For this
standardization, drug concentrations measured in subjects who
received the 5/2.5mg dose were multiplied by 2 for each time
point prior to the pharmacokinetic analyses. This standardiza-
tion method assumes a linear dose–concentration relationship
for oxycodone. Statistical comparisons were only performed on
data for both doses combined and on the subjects who com-
pleted both study conditions (n¼ 8).
RESULTS
Blood plasma pharmacokinetics
The blood plasma pharmacokinetic parameters for oxyco-
done for each dose and the entire study group are shown in
Table 2. Parameters for the oxycodone metabolites, naloxone
and its metabolite naloxone-3-glucuronide are shown in
Table 3. The plasma concentration–time curves for oxycodone
and its metabolites are shown in Figures 1 and 2. Curves for nal-
oxone and naloxone-3-glucuronide are shown in Figure 3.
In patients with ESRD, haemodialysis reduced the plasma
concentrations of unconjugated oxycodone as evidenced by a
significant reduction in AUC6–10 by 21% (T1, 7 ¼ 6.94,
P< 0.001) in the haemodialysis versus non-haemodialysis con-
dition (Table 2), indicating a 26% increase in total clearance
(CL) during haemodialysis (CLh þ CLintrinsic) compared with
no haemodialysis (CLintrinsic). The AUC48 and AUC1 were also
significantly lower after haemodialysis compared with no hae-
modialysis (16%, T1, 7¼ 2.62, P¼ 0.03 and14%, T1, 7¼ 3.66,
P¼ 0.008; respectively) (Table 2). The apparent time-averaged
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total clearance from plasma (CLtot/F) was significantly increased
(þ22%) after haemodialysis compared with no haemodialysis
(T1, 7¼ 3.26, P¼ 0.014) (Table 2). Plasma concentrations of oxy-
codone declinedmuch faster during the 4-h haemodialysis period
compared with after haemodialysis or the no haemodialysis day
(Figure 1). The elimination half-life assessed during haemodialy-
sis 6–10h after dosing (t1/2 d) was significantly shorter than
the terminal elimination half-life (t1/2) after the haemodialysis
FIGURE 1: Plasma concentration–time curves of oxycodone and its metabolite oxymorphone shown as unconjugated (free) and glucuronide
concentrations in patients with ESRD with and without haemodialysis. Oxycodone/naloxone was administered at time ¼ 0 at a dose of 5/
2.5mg in four patients (left-hand panel) and at a dose of 10/5mg in another four patients (right-hand panel). Haemodialysis took place 6–10 h
after drug administration (grey area). Data are mean and SEM. Concentrations of the glucuronidated analytes were determined indirectly by
measuring the analytes after deglucuronidation and subtracting the amount of unconjugated analytes. Concentrations are those of the unconju-
gated analytes without glucuronate.
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FIGURE 2: Plasma concentration–time curves of oxycodone metabolites noroxycodone and noroxymorphone shown as unconjugated (free)
and glucuronide concentrations in patients with ESRD with and without haemodialysis. Oxycodone/naloxone was administered at time ¼ 0 at
a dose of 5/2.5mg in four patients (left-hand panel) and at a dose of 10/5mg in another four patients (right-hand panel). Haemodialysis took
place 6–10 h after drug administration (grey area). Data are mean and SEM. Concentrations of the glucuronidated analytes were determined
indirectly by measuring the analytes after deglucuronidation and subtracting the amount of unconjugated analytes. Concentrations are those of
the unconjugated analytes without glucuronate.
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FIGURE 3: Plasma concentration–time curves of naloxone and naloxone glucuronide in patients with ESRD with and without haemodialysis.
No active, non-glucuronidated naloxone was detected in plasma. Oxycodone/naloxone was administered at time ¼ 0 at a dose of 5/2.5mg in
four patients (left-hand panel) and at a dose of 10/5mg in another four patients (right-hand panel). Haemodialysis took place 6–10 h after
drug administration (grey area). Data are mean and SEM. Concentrations of the naloxone-3-glucuronide were determined indirectly by mea-
suring naloxone after deglucuronidation and subtracting the amount of unconjugated naloxone. Concentrations are those of the unconjugated
analytes without glucuronate.














4 5mg Geometric mean (CV%) 5.8 (11) 4.5 46 (23) 6.4 (22) 428 (10) 21 (14) 95 (25) 97 (23)
Range 5.2–6.5 1.5–6 37–63 4.7–7.5 400–493 18–24 68–120 72–122
4 10mg Geometric mean (CV%) 11 (40) 3.5 75 (36) 4.9 (14) 532 (39) 28 (33) 111 (35) 120 (36)
Range 6.7–16 2–4 54–112 4.4–6 360–761 21–29 77–154 80–168
8 Both dosesc Geometric mean (CV%) 11 (27) 4 59 (38) 5.7 (22) 5.7 (22) 480 (28) 34 (32) 145 (41) 153 (38)
Range 6.7–16 1.5–6 37–112 4.4–7.5 4.4–7.5 360–761 21–48 77–240 80–243
With dialysis
4 5mg Geometric mean (CV%) 7.5 (33) 4 56 (33) 6.5 (40) 4.6 (30) 522 (12) 17 (25) 74 (30) 81 (33)
Range 5.1–10 2–6 43–84 3.9–9.6 3.6–7.1 471–595 14–23 52–103 53–105
5 10mg Geometric mean (CV%) 11 (32) 4 97 35) 4.4 (22) 2.9 (20) 608 (21) 20 (28) 90 (34) 93 (35)
Range 7.4–17 1.5–5 62–139 3.1–5.4 2.4–3.9 480–791 14–28 63–140 65–146
8b Both dosesc Geometric mean (CV%) 13 (36) 3.5 72 (42)* 5.5 (32) 3.9 (39)**,† 573 (20) 27 (39)*** 122 (40)* 131 (44)**
Range 7.4–20 1.5–6 43–139 3.9–9.6 2.4–7.1 472–792 14–46 63–206 65–208
AUC1, area under the plasma concentration–time curve from time zero to infinity; AUC48, AUC from time 0 to 48 h; AUC6–10, AUC from time 6 to 10 h (during dialysis), LCtot/F, ap-
parent total clearance from plasma after oral administration; Cmax, maximum plasma concentration; t1/2, terminal plasma elimination half-life; t1/2 d, plasma elimination half-life during
dialysis (6–10 h); tmax, time to reach Cmax; VD/F, apparent volume of distribution after oral administration.
aMedian; bonly those eight subjects with matching non-dialysis data (excluding one subject without non-dialysis data); cnormalized to 10mg.
*P< 0.05,
**P< 0.01,
***P< 0.001, significant difference compared with the non-dialysis condition.
†
P< 0.05 significant difference compared with t1/2 after dialysis. Statististical tests were only performed on the groups including both doses (n¼ 8).
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(T1, 7¼ 2.96, P¼ 0.02) or compared with that on the day without
haemodialysis (T1, 7 ¼ 4.09, P¼ 0.005) while terminal t1/2 values
did not differ between the haemodialysis and no haemodialysis
conditions (T1, 7 ¼ 0.06, P¼ 0.95) (Table 2). Cmax, Tmax and
apparent volume of distribution (VD/F) values did not differ
significantly between the haemodialysis and no haemodialysis
conditions (T1, 7¼ 2.01, P¼ 0.08; T1, 7¼ 0.0, P¼ 1.0; and T1, 7¼
2.29, P¼ 0.06; respectively) (Table 2).
Oxycodone was present in plasma mostly in its free uncon-
jugated form (Figure 1). Similarly, noroxycodone circulated
mainly in its free form (Figure 2) while oxymorphone
(Figure 1) and noroxymorphone (Figure 2) were present almost
exclusively as glucuronides. Free plasma concentrations of the
active and potent metabolite oxymorphone were therefore very
low (Figure 1). Orally administered naloxone is intended to act
only in the gut, and in this study, we also found that it circulated
exclusively in its inactive glucuronide form while free naloxone
could not be detected in plasma (Figure 3).
Intradialysis kinetics
The haemodialysis pharmacokinetic parameters for all ana-
lytes are shown in Table 4. The haemodialysis blood flow was
kept stable in all patients during dialysis and ranged from 18 to
26 L/h (mean6SD ¼ 21.46 2.5). The extraction ratio for oxy-
codone was 0.476 0.10. The oxycodone clearance by haemo-
dialysis (CLh, r) calculated using the recovery of oxycodone in
the dialysate was 8.46 2.1 L/h and the clearance calculated us-
ing the haemodialysis blood flow and extraction rate (CLh, e)
was 9.86 1.7 L/h. The CLh, r values were smaller than CLh, e
values for all analytes, possibly due to adsorption of analytes to
the filter and tubing (Table 4). In total, 2.5% of the administered
dose of oxycodone was recovered as unconjugated oxycodone
Table 3. Pharmacokinetics of oxycodone metabolites with and without haemodialysis












Oxycodone glucuronide No 4 5 1.8 (34) 12 5.2 (23) 39 (52) 66 (29) NA
No 4 10 3.4 (31) 3 11 (33) 70 (40) 81 (22) NA
Yes 4 5 1.1 (28) 4.5 2.0 (50) 19 (38) 29 (29) NA
Yes 5 10 3.6 (53) 5 5.5 (56) 35 (71) 49 (57) NA
Oxymorphone No 4 5 <LLOQ NA 0 0 0 NA
No 4 10 <LLOQ NA 0 0 0 NA
Yes 4 5 <LLOQ NA 0 0 0 NA
Yes 5 10 <LLOQ NA 0 0 0 NA
Oxymorphone glucuronides No 4 5 b136 16 21 b296 38 b3946 500 b7906 411 19 (51)
No 4 10 b186 9 24 b376 18 b5566 302 b3946 500 21 (39)
Yes 4 5 b7.26 10 24 b156 17 b2466 370 NA NA
Yes 5 10 b126 4.8 24 b206 5.7 b3986 172 NA NA
Noroxycodone No 4 5 4.6 (49) 11 16 (45) 128 (63) 145 (71) 14 (26)
No 4 10 11 (41) 6 40 (49) 231 (76) 275 (67) 13 (23)
Yes 4 5 4.1 (38) 5.5 13 (54) 95 (76) 111 (67) 13 (15)
Yes 5 10 10 (34) 5 27 (43) 155 (82) 187 (75) 12 (33)
Noroxycodone glucuronides No 4 5 b0.66 0.5 3 b0.76 1.2 b8.66 15 NA NA
No 4 10 b2.16 1.6 5 b4.56 4.0 b236 16 NA NA
Yes 4 5 b0.56 0.4 5 b0.96 0.6 b4.66 5.8 NA NA
Yes 5 10 b3.66 2.0 4 b6.96 6.0 b416 36 NA NA
Noroxymorphone No 4 5 b0.46 0.6 11 b1.56 0.6 b116 17 NA NA
No 4 10 b2.66 0.8 21 b8.06 2.4 b916 31 b1296 30 24 (30)
Yes 4 5 b0.46 0.7 5.5 b1.36 1.6 b6.36 7.7 NA NA
Yes 5 10 b2.16 0.6 6 b5.06 2.3 b626 20 b1256 78 35 (64)
Noroxymorphone glucuronides No 4 5 20 (65) 24 42 (64) 664 (61) NA NA
No 4 10 55 (33) 24 127 (21) 1857 (34) NA NA
Yes 4 5 11 (83) 24 15 (74) 335 (93) NA NA
Yes 5 10 42 (36) 24 51 (16) 1388 (35) NA NA
Naloxone No 4 5 <LLOQ NA 0 0 0 NA
No 4 10 <LLOQ NA 0 0 0 NA
Yes 4 5 <LLOQ NA 0 0 0 NA
Yes 5 10 <LLOQ NA 0 0 0 NA
Naloxone glucuronide No 4 5 15 (30) 6.5 54 (30) 358 (38) 371 (38) 9.2 (11)
No 4 10 33 (39) 2 73 (61) 549 (61) 586 (59) 12 (21)
Yes 4 5 17 (20) 5 27 (34) 200 (26) 216 (26) NA
Yes 5 10 37 (43) 3 37 (57) 351 (75) 425 (60) NA
Values are geometric means (CV%). Concentrations of the unconjugated analytes were determined in blood plasma without deglucuronidation. Concentrations of the glucuronidated
analytes were determined indirectly by measuring the analytes after deglucuronidation and subtracting the amount of unconjugated analytes. Concentrations are those of the unconju-
gated analytes without glucuronate.
aMedian values are shown for tmax.
bValues are arithmetric means 6 SDs if geometric mean could not be calculated due to some values ¼ 0.
AUC1, area under the plasma concentration–time curve from time zero to infinity; AUC48, AUC from time 0 to 48 h; AUC6–10, AUC from time 6 to 10 h (during dialysis), LCtot/F, ap-
parent total clearance from plasma after oral administration; Cmax, maximum plasma concentration; LLOQ, lower limit of quantification; tmax, time to reach Cmax; t1/2, terminal plasma
elimination half-life.
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in the dialysate and only 0.3% as oxycodone glucuronide.
Oxymorphone, noroxymorphone and naloxone were almost
exclusively eliminated as glucuronides (1.0, 3.8 and 6.7% of the
dose, respectively) while noroxycodone was mainly eliminated
as unconjugated metabolite (2.6% of the dose, Table 4). Only
2% of the oxycodone dose was recovered as oxycodone or its
metabolites in urine (Table 4).
Pharmacodynamics and safety
Oxycodone/naloxone induced only small changes in subjec-
tive ratings for tiredness, itching, nausea and irritability, with
no relevant differences between study day with or without hae-
modialysis (Supplementary data, Figure S1). Oxycodone/nalox-
one had no effects on pupil function in this study population.
There was a decrease in pupil size during haemodialysis com-
pared with no haemodialysis after the 5/2.5mg but not after the
10/5mg oxycodone/naloxone dose. One female patient devel-
oped urinary retention 5–25 h after dosing on the dialysis day
and consequently stopped participation in the study. Another
patient vomited 1.5, 2.5 and 9 h after dosing and was treated
with an antiemetic. Other attributable adverse drug effects were
(out of a total of 18 drug exposure episodes): nausea (6/18),
tiredness (2/18), headache (2/18) and 1/18 each of relaxed feel-
ing, hiccups, constipation, dizziness, dry mouth and cough.
DISCUSSION
The present study describes for the first time the plasma, dialy-
sate and urine pharmacokinetics of oxycodone/naloxone and
metabolites in patients with ESRD undergoing intermittent
haemodialysis.
Haemodialysis increased the clearance of oxycodone and all
its metabolites. The average plasma extraction ratio for oxyco-
done was 47%. According to the recovery of oxycodone or its
metabolites in the dialysate, 10.6% of the administered dose of
oxycodone was eliminated during 4 h of haemodialysis per-
formed 6–10 h after dosing (Table 4). Oxycodone and its me-
tabolite noroxycodone were eliminated during dialysis mainly
in their unconjugated form. The metabolites oxymorphone and
noroxymorphone as well as naloxone were eliminated almost
exclusively as conjugates. In subjects with normal renal func-
tion, studies have found that on average 7.8% of an oral or 11–
14% of a parenteral dose of oxycodone were excreted in urine as
unconjugated and conjugated oxycodone over 24 h [5, 19]. In
the present patients, 2.8% of the oral oxycodone dose was elimi-
nated in the dialysate within only 4 h, indicating that oxycodone
is quite effectively cleared from plasma by haemodialysis.
Consistent with this observation, the measured plasma half-life
for oxycodone was 3.9 h during haemodialysis, which lies
within the range of reported terminal elimination half-lives (3–
6.7 h) in subjects with normal renal function (Supplementary
data, Figure S2) [1, 5, 6, 13, 16–19, 23–26, 31, 32]. Nevertheless,
the overall exposure (AUC0–48 h) to oxycodone in plasma was
only minimally changed by haemodialysis, consistent with its
predominantly hepatic elimination. Specifically, haemodialysis
reduced the plasma exposure (AUC0–48 h) to oxycodone by
only 16%. Additionally, there was evidence of redistribution
from tissue into the circulation after the end of the haemodialy-
sis session. In the present ESRD patients, the terminal elimina-
tion half-lives (t1/2) of oxycodone and noroxycodone were
approximately 6 and 12 h, respectively. This theoretically trans-
lates into accumulation factors of 1.3 and 2 for oxycodone and
noroxycodone, respectively, were oxycodone/naloxone PR to be
administered every 12 h rather than as a single dose. Consistent
with the present data, the average t1/2 of oxycodone was 7 h
(median ¼ 3.9 h) in 10 patients with ESRD undergoing renal
transplantation [19]. In patients with ESRD, the average t1/2 of
oxycodone (6 h) was only up to 50% longer than in subjects
with normal renal function [5, 6, 13, 16–19, 23–26, 31].
Additionally, in a study in healthy volunteers using the same
oxycodone/naloxone 10/5mg PR formulation, Cmax and
AUC1 values were 10.4 ng/mL and 128 ng	h/mL [1] and there-
fore similar to the values in the present patients with ESRD.
Together, the findings indicate only minimal accumulation of
oxycodone in patients with ESRD. Larger accumulation might
occur for the metabolites with a longer half-life such as noroxy-
codone. However, this is unlikely to be of clinical relevance con-
sidering its low potency as a m-opioid receptor agonist and its















Oxycodone 196 4.8 0.476 0.1 9.86 1.7 8.46 2.1 0.506 0.15 2.56 1.1 0.036 0.02
Oxycodone glucuronide 4.36 2.7 0.546 0.1 116 1.6 6.56 3.6 0.066 0.02 0.36 0.2 0.0026 0.004
Naloxone 0 NA NA NA <0.01 0.036 0.04 <0.001
Naloxone glucuronide 356 13 0.716 0.1 156 0.7 6.66 3.5 0.656 0.28 6.76 3.9 0.096 0.08
Oxymorphone 0 NA NA NA <0.01 0.016 0.03 <0.001
Oxymorphone glucuronides 166 11 0.786 0.05 166 1.2 5.26 2.5 0.236 0.16 1.06 0.9 0.066 0.09
Noroxycodone 236 12 0.406 0.10 8.26 1.5 8.16 2.2 0.586 0.27 2.66 0.7 0.096 0.1
Noroxycodone glucuronides 4.26 5.1 0.376 0.33 7.36 6.3 5.06 7.0 0.056 0.07 0.26 0.2 0.086 0.1
Noroxymorphone 3.46 2.6 0.546 0.07 116 2.0 5.36 2.6 0.056 0.06 0.26 0.3 0.0076 0.007
Noroxymorphone glucuronides 376 19 0.786 0.08 166 0.9 7.36 2.5 0.856 0.47 3.86 2.0 0.096 0.1
Values are mean 6 SD in nine patients. Concentrations of the glucuronidated analytes were determined indirectly by measuring the analytes after deglucuronidation and subtracting
the amount of unconjugated analytes. Concentrations are those of the unconjugated analytes without glucuronate.
AUCart, 6–10 h, area under the plasma concentration-time curve from 6 to 10 h after dosing during haemodialysis (arterial ¼ line entering the dialyser); E, drug extraction ratio by hae-
modialysis; CLh, e, clearance by haemodialysis calculated by the extraction method, CLh, r, clearance by haemodialysis calculated by the recovery method; Ad, amount of analyte recov-
ered in the dialysate; Au, amount of analyte recovered in urine; NA, not assessed.
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lower brain penetration [10]. Nevertheless, a study using re-
peated doses is needed to further assess the accumulation of
oxycodone and its metabolites in patients with ESRD.
It has been suggested that oxymorphone and noroxymor-
phone may contribute to the analgesic effects of oxycodone [10,
20, 33]. However, the present study showed that concentrations
of the active metabolite oxymorphone and noroxymorphone in
their unconjugated form were very low. Additionally, the 3-glu-
curonides of these two metabolites are also likely inactive at the
m-opioid receptor [11]. Therefore, although metabolites of oxy-
codonemay accumulate due to their longer half-lives in patients
with ESRD, opioidergic effects are unlikely. This is in contrast
to morphine, where the active morphine-6-glucuronide metab-
olite accumulates [34–36]. Taken together, our findings do not
indicate clinically relevant accumulation of oxycodone or its ac-
tive free metabolites in patients with ESRDwith or without hae-
modialysis. Therefore, oxycodone can be dosed similarly in
patients with ESRD and in patients without renal impairment,
according to the severity of their pain. The study also indicates
that oxycodone is a suitable opioid in patients with ESRD on
haemodialysis as similarly proposed for fentanyl, buprenor-
phine or methadone [37]. Furthermore, due to oxycodone’s low
protein binding, patients with hypoalbuminaemia are unlikey
to develop rebound pain during or after dialysis, as has been
shown for buprenorphine [38]. So, in line with a single previ-
ously available case report [27], the present data show that oxy-
codone is removed during haemodialysis, but probably not to
an extent necessitating additional dosing.
In subjects with normal renal function, 40% of the admin-
istered oxycodone can be recovered in urine as oxycodone or its
metabolites [9]. In contrast, in the present ESRD patients, the
urinary recovery of oxycodone and its metabolites in their
unconjugated and conjugated forms was only 2% of the ad-
ministered dose of oxycodone. This is consistent with the
previously reported average 1% urinary recovery of unconju-
gated oxycodone in ESRD patients undergoing renal transplan-
tation compared with 11% in patients with normal renal
function [19].
Some studies reported reduced effects of oxycodone in
CYP2D6 poor metabolizers compared with extensive metabo-
lizers [20, 33, 39] or in the presence of CYP2D6 inhibitors [33]
while others could not confirm these findings [10, 17, 40, 41].
Although we determined CYP2D6 genotypes and included
both extensive and poor metabolizers, the sample size was too
small to determine the role of CYP2D6 in the pharmacokinetics
and pharmacodynamics of oxycodone. Additionally, oxyco-
done did not induce robust changes in pupil size at the low dose
used in the present patients with ESRD and therefore does not
seem to be a good biomarker for the opioid effect in these
patients in contrast to data from previous studies in healthy and
younger subjects [13, 23–25, 31]. Therefore, the pharmacody-
namic measures obtained in the present study did not allow
for pharmacokinetic–pharmacodynamic modelling or other
evaluations of the effects of CYP2D6 function or haemodialysis
on the subjective or other pharmacodynamic effects of
oxycodone.
In the present study adverse effects of oxycodone included
nausea, vomiting and urinary retention as also commonly
reported in studies in healthy subjects [9, 31]. There were no
differences in tolerability of oxycodone/naloxone on days with
or without haemodialysis.
A strength of the present study was the use of a within-
subject design that allowed us to assess the impact of haemo-
dialysis within the same patients and increased study power.
Limitations were the small sample size and that the study did
not include an age-matched comparator group with normal re-
nal function.
In conclusion, oxycodone is eliminated during haemodialy-
sis, but not to an extent necessitating additional dosing. The
pharmacokinetics of oxycodone in patients with ESRD and the
absence of unconjugated active metabolites indicate that oxyco-
done can be used at usual doses.
SUPPLEMENTARY DATA
Supplementary data are available at ndt online.
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